EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease

Gastroenterología y Hepatología · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles